Table 1.
Demographic and lung function parameters at baseline (test day 1), briefly before discharge from the acute hospital stay
| LuTXr sample n/mean (SD) |
|
|---|---|
| Number of patients | 50 |
| Age (in years) | 38.4 (12.8) |
| Body mass index (kg/cm2) | 19.57 (3.9) |
| Disease causing LuTX (n) | |
| Cystic fibrosis | 26 |
| Chronic pulmonary disease | 7 |
| Chronic pulmonary hypertension | 8 |
| Others | 9 |
| Medication number of patients (in mg) | |
| Glucocorticoid (prednisolone) (n = 50) | 36.22 (48.08) |
| Tacrolimus (n = 48) | 11.56 (5.92) |
| Cyclosporine (n = 1) | 400.00 (–) |
| Mycophenolate mofetil (n = 26) | 697 (1122) |
| Time elapsed from | |
| Transplantation to first test (days) | 31.4 (33.1) |
| Duration at ICU (days) | 16.1 (30.1) |
| Baseline to 1st retest (days) | 1.5 (1.4) |
| Baseline to end of rehabilitation (days) | 77.4 (35.9) |
| Lung function related variables (discharge from acute hospital): | |
| Lung vital capacity (l) | 1.9 (0.7) |
| Lung vital capacity (% predicted) | 42.9 (12.7) |
| FEV1s (l) | 1.7 (0.6) |
| FEV % | 45.4 (13.0) |
| MEF50 (l) | 2.9 (1.3) |
| MEF50 (%) | 64.1 (28.8) |
FEV1s forced expiration volume in 1 s, MEF50 mean expiratory flow 50%